(10)ALK抑制剂:克唑替尼(Crizotinib)是ALK抑制剂,适合对BV耐药的ALK+ALCL患者[5]。克唑替尼联合化疗治疗R/R ALK+系统性ALCL的ORR为81.3%。克唑替尼联合化疗与单纯化疗的2年PFS率分别为68.7%和45%,OS率分别为86.1%和78.9%[50]。. Here, ALK is linked to anaplastic large cell lymphoma.